Characteristics of included studies
| Study . | Country . | No. control subjects . | No. ALL survivors . | Mean age at diagnosis, y* . | Mean time since diagnosis, y* . | Mean age at final evaluation, y* . | ALL treatment protocol . |
|---|---|---|---|---|---|---|---|
| 19† | UK | 132 | 289 | 5.5 | 5.6 | 10.0 | MRC-UKALL XI |
| 27 | Finland | 45 | 20 | 6 | 17 | 23 | NOPHO ALL 1992 |
| 28 | US | 10 | 10 | 3.3 | 5.3 | 10.3 | Modified ALinC #12 (SWOG) |
| 29†,‡ | Netherlands | 28 | 40 | 6.4 | NR | 11.2 | DCOG ALL-9 |
| 30†,‡ | Netherlands | 225 | 17 | 3.5 | NR | 9.3 | DCLSG ALL VI |
| 11‡ | Netherlands | 225 | 20 | 3.4 | 7.2 | 10.3 | DCLSG ALL VII |
| 31 | Norway | 35 | 35 | 3.8 | 7.7 | 11.5 | NOPHO ALL 1992 |
| 32‡ | New Zealand | 21 | 21 | 4.1 | NR | 9.4 | ANZCCSG V and VI |
| 33 | Norway | 42 | 40 | 4.0 | 7.9 | 11.8 | NOPHO ALL 1992 |
| 34 | UK | 17 | 17 | 4.0 | 5.0 | 9.7 | MRC-UKALL XI |
| Study . | Country . | No. control subjects . | No. ALL survivors . | Mean age at diagnosis, y* . | Mean time since diagnosis, y* . | Mean age at final evaluation, y* . | ALL treatment protocol . |
|---|---|---|---|---|---|---|---|
| 19† | UK | 132 | 289 | 5.5 | 5.6 | 10.0 | MRC-UKALL XI |
| 27 | Finland | 45 | 20 | 6 | 17 | 23 | NOPHO ALL 1992 |
| 28 | US | 10 | 10 | 3.3 | 5.3 | 10.3 | Modified ALinC #12 (SWOG) |
| 29†,‡ | Netherlands | 28 | 40 | 6.4 | NR | 11.2 | DCOG ALL-9 |
| 30†,‡ | Netherlands | 225 | 17 | 3.5 | NR | 9.3 | DCLSG ALL VI |
| 11‡ | Netherlands | 225 | 20 | 3.4 | 7.2 | 10.3 | DCLSG ALL VII |
| 31 | Norway | 35 | 35 | 3.8 | 7.7 | 11.5 | NOPHO ALL 1992 |
| 32‡ | New Zealand | 21 | 21 | 4.1 | NR | 9.4 | ANZCCSG V and VI |
| 33 | Norway | 42 | 40 | 4.0 | 7.9 | 11.8 | NOPHO ALL 1992 |
| 34 | UK | 17 | 17 | 4.0 | 5.0 | 9.7 | MRC-UKALL XI |
ANZCCSG, Australian and New Zealand Children’s Cancer Study Group; DCLSG, Dutch Childhood Leukemia Study Group; DCOG, Dutch Childhood Oncology Group; MRC-UKALL, Medical Research Council Acute Lymphoblastic Leukemia Trial; NOPHO, Nordic Society of Pediatric Hematology and Oncology; NR, not reported; SWOG, Southwestern Oncology Group; UK, United Kingdom; US, United States.
A median value is provided if the mean was not available.
Longitudinal study in which data from the last time point was used.
Not all age data were reported.